- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05697055
A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection
A Prospective Multicenter, Randomized, Controlled Clinical Trial of the Safety and Efficacy of Azvudine vs. Nirmatrelvir-Ritonavir in Hospitalized Patients With Moderate to Severe COVID-19 Infection
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Bing Leng
- Phone Number: +86531-68776461
- Email: taozilb@163.com
Study Contact Backup
- Name: Chengwu Shen
- Phone Number: +86531-68778252
- Email: scw810@163.com
Study Locations
-
-
Shandong
-
Jinan, Shandong, China
- Recruiting
- Shandong Provincial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hospitalized patients of ≥18 years old, regardless of gender or race;
- Patients who have a positive SARS-CoV-2 test result;
Diagnosed with moderate or severe COVID-19 infection according to the diagnostic criteria from the "Diagnosis and treatment program trial version 10 guidelines" issued by the National Health Commission of the People's Republic of China. Including:
①Moderate: continuous high fever for more than 3 days or/and cough, shortness of breath, etc., but the breathing frequency (RR) is less than 30 times/minute, and the oxygen saturation when inhaling air at rest is > 93%. Imaging shows the characteristic manifestations of COVID-19 pneumonia.
② Severe: Adults meet any of the following requirements: A, shortness of breath, RR≥ 30 times/minute; B, the oxygen saturation when inhaling air at rest is ≤ 93%; C, Arterial partial oxygen pressure (PaO2)/ Fraction of inspiration O2 (FiO2) ≤300mmHg (1mmHg=0.133kPa), and PaO2/FiO2 should be corrected according to the following formula for areas above 1000 m :PaO2/FiO2× [760/ atmospheric pressure (mmHg)]; D, the clinical symptoms were gradually aggravated, and the lung imaging showed that the lesion progressed significantly within 24 ~ 48 hours > 50%.
- Join this study voluntarily.
- Each subject must sign an informed consent form (ICF) indicating that he/she understands the purpose and procedure of the study and is willing to participate in the study. Considering the patient's condition, the ICF may be signed by the legal representative.
Exclusion Criteria:
- Allergic to the drugs involved;
- Pregnancy or lactation;
- Diagnosed or suspected critical COVID-19 infection;
- Child-Pugh C of liver function or estimated glomerular filtration rate (eGFR) less than 30mL/min during screening;
- Receive SARS-CoV-2 monoclonal antibody therapy or other antiviral therapy;
- The subject and/or authorized family members refused to receive anti-COVID-19 treatment;
- Any life-threatening disease or organ system dysfunction that the researcher thinks can harm the safety of the subjects and expose the research results to unnecessary risks; drug addicts, uncontrolled mental illness or cognitive dysfunction.
- Join other similar clinical researchers within 3 months;
- Patients who were not considered suitable for inclusion by the researchers (such as patients who were expected to be unable to adhere to the treatment due to financial problems).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Azvudine
|
5mg orally, once a day, for no more than 14 days
|
Active Comparator: Nirmatrelvir-Ritonavir
|
Nirmatrelvir 300mg combined with Ritonavir 100mg every 12 hours for 5 days.
For patients with 30≤ eGFR < 60 ml/min, it should be reduced to150mg/100mg Nirmatrelvir-Ritonavir every 12 hours for 5 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time and proportion of patients with COVID-19 infection to have sustained clinical recovery
Time Frame: Up to 28 days
|
Up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time and proportion of the nucleic acid negative conversion
Time Frame: Days 3, 6, 9, 12, 15, 18, 21, 24, 27
|
Days 3, 6, 9, 12, 15, 18, 21, 24, 27
|
Time and proportion of chest CT image improvement
Time Frame: Days 6, 12, 18, 24
|
Days 6, 12, 18, 24
|
Time and proportion of oxygenation index improvement
Time Frame: Up to 28 days
|
Up to 28 days
|
Length of stay
Time Frame: Up to 28 days
|
Up to 28 days
|
Proportion of progression to critical COVID-19 and death from any cause
Time Frame: Up to 28 days
|
Up to 28 days
|
Time of COVID-19 related symptom score and World Health Organization (WHO) clinical progress scale score. Time and proportion of clinical recovery, symptom resolution and regression of major symptoms
Time Frame: Up to 28 days
|
Up to 28 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Ritonavir
Other Study ID Numbers
- SWYX2023022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Azvudine
-
Shanghai Henlius BiotechHuashan Hospital; Shanghai Fosun Pharmaceutical Industrial Development Co....Not yet recruiting
-
Peking Union Medical College HospitalNot yet recruiting
-
Qianfoshan HospitalRecruitingCOVID-19 Respiratory InfectionChina
-
Southeast University, ChinaHohhot First Hospital, Hohhot, Inner Mongolia, ChinaRecruiting
-
HRH Pharmaceuticals LimitedGALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil and other collaboratorsCompleted
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityActive, not recruiting
-
Shanghai Henlius BiotechShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.; HeNan Sincere...RecruitingSARS-CoV-2 InfectionMalaysia, Philippines
-
Shanghai Henlius BiotechHuashan Hospital; Shanghai Fosun Pharmaceutical Industrial Development Co.... and other collaboratorsRecruiting
-
HRH Pharmaceuticals LimitedGALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil and other collaboratorsCompleted
-
Biosense Webster EMEACompletedAtrial FibrillationItaly